We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+19.25%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$421M
AUM Growth
-$37.1M
Cap. Flow
-$66.7M
Cap. Flow %
-15.87%
Top 10 Hldgs %
82.19%
Holding
34
New
3
Increased
4
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$40.3M
2
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$11M
3
VXX
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
+$3.61M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$2.87M
5
PTCT icon
PTC Therapeutics
PTCT
+$2.69M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$30.6M
2
BPMC
Blueprint Medicines
BPMC
+$22.1M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$17.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$12.8M
5
ESPR
Esperion Therapeutics
ESPR
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 82.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$65.7M 15.63%
800,000
-228,763
-22% -$17.2M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$46.8M 11.13%
500,000
-500,000
-50% -$30.6M
ESPR
3
DELISTED
Esperion Therapeutics
ESPR
$46.3M 11.01%
1,000,000
-275,000
-22% -$10.1M
MDCO
4
DELISTED
Medicines Co
MDCO
$46.2M 10.98%
1,215,000
– –
MGNX icon
5
MacroGenics
MGNX
$235M
$37M 8.81%
+2,115,000
New +$40.3M
PTCT icon
6
PTC Therapeutics
PTCT
$5.64B
$31.2M 7.41%
1,700,000
+200,000
+13% +$2.69M
ONC
7
BeOne Medicines Ltd
ONC
$32.8B
$27M 6.42%
600,000
-250,000
-29% -$9.85M
MDCO
8
CALL
DELISTED
Medicines Co
MDCO
$20.2M 4.8%
530,600
-153,100
-22% -$6.82M
BPMC
9
DELISTED
Blueprint Medicines
BPMC
$12.7M 3.01%
250,000
-520,159
-68% -$22.1M
INCY icon
10
Incyte
INCY
$24.2B
$12.6M 2.99%
100,000
– –
GTHX
11
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$11M 2.61%
+629,179
New +$11M
PBYI icon
12
Puma Biotechnology
PBYI
$404M
$8.74M 2.08%
100,000
– –
LJPC
13
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.96M 1.89%
267,500
+100,100
+60% +$2.87M
NGNE icon
14
Neurogene
NGNE
$656M
$7.39M 1.76%
26,250
-17,638
-40% -$5.05M
SBBP
15
DELISTED
Strongbridge Biopharma plc.
SBBP
$6.72M 1.6%
940,000
– –
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$6.47M 1.54%
125,000
+25,000
+25% +$1.59M
KURA icon
17
Kura Oncology
KURA
$800M
$4.96M 1.18%
533,251
– –
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.79M 0.9%
1,037,994
– –
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.69B
$3.27M 0.78%
234,220
– –
VXX
20
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
$3.19M 0.76%
+62,500
New +$3.61M
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.77M 0.66%
29,286
+14,286
+95% +$1.64M
BLPH
22
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2.49M 0.59%
123,810
– –
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
$2.45M 0.58%
425,000
-352,202
-45% -$1.5M
NBRV
24
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.85M 0.44%
707
– –
EIGR
25
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.09M 0.26%
4,611
– –
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Boxer Capital held 34 positions worth $421M, down 8.1% from $458M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Boxer Capital withdrew a net $66.7M in Q2 2017, closing 7 positions and reducing 9 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $12.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier.

Against the trend, Boxer Capital opened a new position in MacroGenics worth $37M.

  • Boxer Capital's largest Q2 2017 buy was MacroGenics: 2,115,000 shares worth $37M.
  • Boxer Capital added most to La Jolla Pharmaceutical Company in Q2 2017, an estimated $2.87M increase.
  • Boxer Capital's biggest Q2 2017 reduction was Clovis Oncology, Inc., cutting an estimated $30.6M.
  • Boxer Capital fully exited Alnylam Pharmaceuticals in Q2 2017, selling an estimated $12.8M.
  • Boxer Capital's ten largest holdings make up 82% of its $421M portfolio in Q2 2017.
  • Boxer Capital opened 3 new positions and closed 7 in Q2 2017.
  • Boxer Capital's portfolio value fell 8.1% quarter-over-quarter to $421M.

Based on Boxer Capital's 13F filing for Q2 2017, filed 14 Aug 2017.